Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET overexpression + KDR overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MET exon 14 mutation (33)

MET mutation (13)

EGFR mutation + MET mutation (2)

MET exon 14 mutation + EGFR exon 20 insertion (2)

EGFR T790M + MET mutation (1)

EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation (1)

EGFR mutation + MET Y1003N (1)

EGFR wild-type + MET wild-type (1)

MET exon 14 mutation + KRAS G12A (1)

MET exon 14 mutation + TP53 mutation (1)

MET mutation + AXL mutation (1)

KDR Q472H + KIT M541L (1)

KDR mutation (1)

KDR rs1870377 (1)

KDR rs2071559 (1)

KDR rs2305945 (1)

MET exon 14 skipping mutation + EGFR G709T (0)

ROS rearrangement + MET D1246N (0)

MET exon 14 mutation (33)

MET mutation (13)

EGFR mutation + MET mutation (2)

MET exon 14 mutation + EGFR exon 20 insertion (2)

EGFR T790M + MET mutation (1)

EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation (1)

EGFR mutation + MET Y1003N (1)

EGFR wild-type + MET wild-type (1)

MET exon 14 mutation + KRAS G12A (1)

MET exon 14 mutation + TP53 mutation (1)

MET mutation + AXL mutation (1)

KDR Q472H + KIT M541L (1)

KDR mutation (1)

KDR rs1870377 (1)

KDR rs2071559 (1)

KDR rs2305945 (1)

MET exon 14 skipping mutation + EGFR G709T (0)

ROS rearrangement + MET D1246N (0)

›

MET overexpression + KDR overexpression	Ovarian Cancer	MET overexpression + KDR overexpression	Ovarian Cancer	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B	bevacizumab Resistant: B - Late Trials bevacizumab Resistant : B
MET overexpression + KDR overexpression	Glioblastoma	MET overexpression + KDR overexpression	Glioblastoma	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3